Notable
Soquelitinib · Hidradenitis Suppurativa
Recruitment opened
Corvus Pharmaceuticals, Inc.Phase 1 NCT07828860 Registry history of NCT07828860 on ClinicalTrials.gov (opens the registry)
Updated
4 active trials 3 recruiting 1 Phase 3 3 disease areas 2 changes in 30 days
2 trials changed in the last 30 days: 0 stopped, 1 with a notable change, 1 with a minor change only.
Recruitment opened
Corvus Pharmaceuticals, Inc.Phase 1 NCT07828860 Registry history of NCT07828860 on ClinicalTrials.gov (opens the registry)
Updated
Trial sites expanded: 34 → 37 locations
Corvus Pharmaceuticals, Inc.Phase 3 NCT06561048 Registry history of NCT06561048 on ClinicalTrials.gov (opens the registry)
Updated
| First posted | Trial | Phase | Status |
|---|---|---|---|
| 2026-09-18 | NCT07828860 Safety and Efficacy of Soquelitinib in Adults With Hidradenitis Suppurativa | Phase 1 | Recruiting |
| Phase 1 | 2 | |
| Phase 2 | 1 | |
| Phase 3 | 1 |
| NCT ID | Title | Condition | Status | Updated |
|---|---|---|---|---|
| Phase 3 | ||||
| NCT06561048 | Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral… | Peripheral T-Cell Lymphoma, Not Otherwise Specified | Recruiting | 2026-09-25 |
| Phase 2 | ||||
| NCT07441395 | Study to Evaluate Soquelitinib in Participants With Moderate to Severe AD | Atopic Dermatitis | Recruiting | 2026-03-05 |
| Phase 1 | ||||
| NCT07828860 | Safety and Efficacy of Soquelitinib in Adults With Hidradenitis Suppurativa | Hidradenitis Suppurativa (HS) | Recruiting | 2026-09-22 |
| NCT03952078 | A Dose Escalation Study Evaluating CPI-818 in Relapsed/Refractory T-Cell Lymphoma | T-cell Lymphoma | Active, Not Recruiting | 2025-04-16 |
Non-Hodgkin Lymphoma (2) · Atopic Dermatitis (1) · Hidradenitis Suppurativa (1)